IXICO plc IXICO announces updates to client contracts (7335X)
23 Diciembre 2019 - 01:00AM
UK Regulatory
TIDMIXI
RNS Number : 7335X
IXICO plc
23 December 2019
23 December 2019
IXICO plc
("IXICO" or the "Company")
IXICO announces updates to client contracts
GBP2.4 million expansion of study programmes with two large
pharma client contracts
IXICO plc (AIM: IXI), the data analytics company delivering
insights in neuroscience, today announces:
-- cGBP1.8 million extension to a Phase III study in
Huntington's Disease (HD), previously announced in September 2018;
and
-- cGBP0.6 million extension to a study programme in Progressive
Supranuclear Palsy (PSP), previously announced in October 2019.
Giulio Cerroni, Chief Executive Officer of IXICO, commented:
"HD and PSP are devastating neurological conditions, currently
with no cure, and we are pleased to build momentum in our mission
to support our clients in delivering data analytics in these
challenging areas of rare, neurodegenerative disease. Our services
will enable them to measure the impact of the trialled drugs with
greater confidence and potentially unlock new insights into disease
progression.
"Following the recent announcement of our strong trading results
for FY19, the expansion of these work programmes for two large
pharma clients is further evidence of the value that we deliver
through our proprietary AI data analytics and our ability to scale
our operations to meet increasing size and complexity of clinical
trials as they progress through clinical development."
For further information please contact:
IXICO plc +44 (0) 20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0) 20 7397 8900
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Russell Kerr (Sales)
Optimum Strategic Communications +44 (0) 203 950 9144
Mary Clark, Supriya Mathur, Manel Mateus
IXICO@optimumcomms.com
About IXICO
IXICO's purpose is to advance medicine and human health by
turning data into clinically meaningful information, providing
valuable new insights in neuroscience.
Our goal is to be a leading proponent in the use of AI in
clinical development, to improve biopharma R&D productivity
through the adoption of breakthrough data analytics in precision
healthcare. Through the deployment of novel AI algorithms, we
analyse and interpret brain scans and digital biosensor data to
enable better trial design, patient selection and ultimately
clinical outcomes across all phases of clinical evaluation. Our
data analytics services are deployed on some of the most important
clinical trials in neuroscience, providing valuable insights to
disease progression and patient safety, enabling our clients to
make better informed decisions earlier in the clinical development
pathway.
More information is available on www.IXICO.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
CNTCKKDQOBDDABB
(END) Dow Jones Newswires
December 23, 2019 02:00 ET (07:00 GMT)
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024